| Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib JA Woyach, RR Furman, TM Liu, HG Ozer, M Zapatka, AS Ruppert, L Xue, ... New England Journal of Medicine 370 (24), 2286-2294, 2014 | 1360 | 2014 |
| Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes JA Dubovsky, KA Beckwith, G Natarajan, JA Woyach, S Jaglowski, ... Blood, The Journal of the American Society of Hematology 122 (15), 2539-2549, 2013 | 828 | 2013 |
| Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation TM Liu, JA Woyach, Y Zhong, A Lozanski, G Lozanski, S Dong, E Strattan, ... Blood, The Journal of the American Society of Hematology 126 (1), 61-68, 2015 | 200 | 2015 |
| Methods in DNA methylation profiling T Zuo, B Tycko, TM Liu, HJL Lin, THM Huang Epigenomics 1 (2), 331-345, 2009 | 119 | 2009 |
| Epigenetic silencing mediated through activated PI3K/AKT signaling in breast cancer T Zuo, TM Liu, X Lan, YI Weng, R Shen, F Gu, YW Huang, ... Cancer research 71 (5), 1752-1762, 2011 | 71 | 2011 |
| Estrogen-mediated epigenetic repression of the imprinted gene cyclin-dependent kinase inhibitor 1C in breast cancer cells BAT Rodriguez, YI Weng, TM Liu, T Zuo, PY Hsu, CH Lin, AL Cheng, ... Carcinogenesis 32 (6), 812-821, 2011 | 50 | 2011 |
| STAT2 hypomorphic mutant mice display impaired dendritic cell development and antiviral response LS Chen, PC Wei, T Liu, CH Kao, LM Pai, CK Lee Journal of biomedical science 16, 1-11, 2009 | 30 | 2009 |
| OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells TM Liu, Y Ling, JA Woyach, K Beckwith, YY Yeh, E Hertlein, X Zhang, ... Blood, The Journal of the American Society of Hematology 125 (2), 284-295, 2015 | 29 | 2015 |
| A Breakthrough Therapy in Relapsed Chronic Lymphocytic Leukemia: the Combination of Idelalisib and Rituximab Y Zhong, TM Liu, AJ Johnson the New England Journal of Medicine 1, 220, 2014 | 2 | 2014 |
| OSU-T315, An Integrin-Linked Kinase (ILK) Inhibitor, Induces Apoptosis By Targeting B Cell Receptor and CD49d Mediated AKT/ERK Activation In Chronic Lymphocytic Leukemia Cells TM Liu, YH Ling, MA Phelps, JA Woyach, EK Hertlein, WH Towns, ... Blood 122 (21), 2523-2523, 2013 | 1 | 2013 |
| Kinase Targeting Therapies in Chronic Lymphocytic Leukemia: Mechanisms of Acquired Ibrutinib Resistance and the Pre-Clinical Development of OSU-T315 TM Liu The Ohio State University, 2014 | | 2014 |
| Ibrutinib inhibits Interleukin-2 inducible kinase, driving a Th1 selective pressure in human leukemia patients that serves to alleviate tumor-induced immunosupression. JA Dubovsky, KA Beckwith, G Natarajan, JA Woyach, S Jaglowski, ... Cancer Research 73 (8_Supplement), 492-492, 2013 | | 2013 |
| Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1 selective A Mishra, MA Caligiuri, AR Satoskar, JJ Buggy, N Muthusamy, ... | | |
